Key result
Current pulmonary arterial hypertension therapies target prostacyclin, endothelin, and nitric oxide pathways, with upfront combination therapy now recommended to improve right ventricular function.
Why the study?
Although over 10 drugs have been approved for pulmonary arterial hypertension, no medical treatment is currently curative, motivating a comprehensive review of available therapies and clinical therapeutic strategies.
This comprehensive review outlines the modern therapeutic landscape for pulmonary arterial hypertension, emphasizing the importance of upfront combination therapy and risk stratification based on recent guidelines.
The several randomized controlled trials (RCTs) conducted in the last 25 years in the field of pulmonary arterial hyper- tension (PAH) have led to the approval of over 10 drugs, which seek to restore the right balance between vasoconstrictor and vasodilator factors, and to the consequent increase of the median survival. However, no medical treatment is currently curative. Ongoing research is focusing on how to preserve right ventricle (RV) function, curbing the inexorable progres- sion of the disease towards right heart failure and death. Below, we provide a comprehensive review of the current available PAH specific therapies and briefly report the therapeutic strategies adopted by PH specialists in clinical practice.
No takes yet. Share an insight, caveat, or question.
Manzi et al. (2022) conducted a review in Pulmonary arterial hypertension. PAH specific therapies was evaluated. Current pulmonary arterial hypertension therapies target prostacyclin, endothelin, and nitric oxide pathways, with upfront combination therapy now recommended to improve right ventricular function.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: